Carlo Rizzuto
Director/Board Member bij CENTURY THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Carlo Rizzuto is currently the Chief Executive Officer & Director at Kyras Therapeutics, Inc. He is also a Managing Director at Versant Venture Management LLC, a Director at Pandion Operations, Inc., Jnana Therapeutics, Inc., Gotham Therapeutics Corp., and 858 Therapeutics, Inc. Additionally, he serves as an Independent Director at Century Therapeutics, Inc., a Director at Stablix, Inc., and the President & Director at FirstLight Bio, Inc. Dr. Rizzuto is also a Director at Nested Therapeutics, Inc. and an Advisor at The New York City Investment Fund Manager, Inc. In his former positions, Dr. Rizzuto served as the CEO of Highline Therapeutics, Inc. from 2015 to 2022.
He was also a Director at Venatorx Pharmaceuticals, Inc. from 2017 to 2022.
Prior to that, he worked as a Director-Global Program at Novartis Pharmaceuticals Corp.
from 2010 to 2012.
He also served as an Independent Director at Pandion Therapeutics, Inc. from 2018 to 2021.
Dr. Rizzuto currently holds positions as a Director at Century Therapeutics, Inc., Graphite Bio, Inc., and McKinsey & Co., Inc. He was a Business Development Manager at engeneOS, Inc. from 2000 to 2002 and the Chief Business Officer at Anokion SA from 2014 to 2017.
Dr. Rizzuto completed his undergraduate studies at the University of Virginia and obtained a doctorate degree from Harvard University in 1999.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
-.--% | 01-02-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
27-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Carlo Rizzuto
Bedrijven | Functie | Begin |
---|---|---|
CENTURY THERAPEUTICS, INC. | Director/Board Member | 01-03-2018 |
The New York City Investment Fund Manager, Inc.
The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Consultant / Advisor | - |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | Director/Board Member | - |
FirstLight Bio, Inc. | President | - |
858 Therapeutics, Inc.
858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Director/Board Member | - |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Director/Board Member | - |
Gotham Therapeutics Corp.
Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Director/Board Member | - |
Pandion Operations, Inc.
Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Jnana Therapeutics, Inc.
Jnana Therapeutics, Inc. BiotechnologyHealth Technology Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA. | Director/Board Member | - |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Eerdere bekende functies van Carlo Rizzuto
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Carlo Rizzuto
University of Virginia | Undergraduate Degree |
Harvard University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CENTURY THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 19 |
---|---|
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Commercial Services |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
The New York City Investment Fund Manager, Inc.
The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Finance |
engeneOS, Inc.
engeneOS, Inc. Miscellaneous Commercial ServicesCommercial Services EngeneOS, Inc. provides research and development services. The private company is based in Waltham, MA. The company was founded by John Schwartz. | Commercial Services |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Highline Therapeutics, Inc.
Highline Therapeutics, Inc. BiotechnologyHealth Technology Part of Versant Venture Management LLC, Highline Therapeutics, Inc. operates as a biotech incubator. The private company is based in New York, NY. | Health Technology |
Kyras Therapeutics, Inc.
Kyras Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kyras Therapeutics, Inc. operates as a biopharmaceutical company that develops drugs for incurable cancers and developmental disorders caused by RAS gene mutations. The company was founded by Brent R. Stockwell in 2015 and is headquartered in New York, NY. | Health Technology |
Pandion Operations, Inc.
Pandion Operations, Inc. Miscellaneous Commercial ServicesCommercial Services Pandion Operations, Inc. develops drugs for autoimmune, inflammatory, and transplant indications. The company was founded by Anthony J. Coyle, Jo Viney, Alan Crane, and David Sachs in 2017 and is headquartered in Cambridge, MA. | Commercial Services |
Jnana Therapeutics, Inc.
Jnana Therapeutics, Inc. BiotechnologyHealth Technology Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA. | Health Technology |
Gotham Therapeutics Corp.
Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Health Technology |
858 Therapeutics, Inc.
858 Therapeutics, Inc. BiotechnologyHealth Technology 858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA. | Health Technology |
Pandion Therapeutics, Inc.
Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
Graphite Bio, Inc.
Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Commercial Services |
FirstLight Bio, Inc. | |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | Commercial Services |